<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809536</url>
  </required_header>
  <id_info>
    <org_study_id>A5361031</org_study_id>
    <nct_id>NCT00809536</nct_id>
  </id_info>
  <brief_title>Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Pharmacokinetics Of PD 0332334 And Metformin When Administered Concurrently In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To estimate the effects of multiple doses of PD 0332334 on the elimination of a single
           dose of metformin from the body

        2. To estimate the effects of multiple doses of metformin on the elimination of a single
           dose of PD 0332334 from the body

        3. To evaluate the safety and tolerability when PD 0332334 and metformin are administered
           at the same time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:

      Additional Study Purpose Details: To assess the pharmacokinetics of metformin and PD 0332334
      with concurrent administration.

      On February 18th 2009, a decision to terminate further development for PD 0332334 was
      communicated to investigators in this study. The decision to terminate this study was not
      based on any safety concerns.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Please Detailed Description for termination reason.
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metformin and PD 0332334 area under the curve (AUC) from time 0 to infinity (AUCinf)</measure>
    <time_frame>Days 1 through 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin and PD 0332334 AUC from 0 to last quantifiable concentration (AUClast)</measure>
    <time_frame>Days 1 through 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin and PD 0332334 half-life (t1/2)</measure>
    <time_frame>Days 1 through 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin and PD 0332334 maximum plasma concentration</measure>
    <time_frame>Days 1 through 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical safety laboratories</measure>
    <time_frame>Days 1 through 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, duration and severity of adverse events when study medications administered alone and concurrently</measure>
    <time_frame>Days 1 through 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation due to adverse events when study medications administered alone and concurrently</measure>
    <time_frame>Days 1 through 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECGs</measure>
    <time_frame>Days 1 through 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Days 1 through 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>imagabalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Single, oral, 500 mg of metformin immediate release</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD 0332334</intervention_name>
    <description>500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD 0332334</intervention_name>
    <description>Single, oral, 300 mg dose of PD 0332334 immediate release formulation</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nonsmokers

          -  Male or female adults

        Exclusion Criteria:

          -  Current or history of significant medical illness

          -  Smokers

          -  Illicit drug use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5361031&amp;StudyName=Investigation%20Of%20How%20PD%200332334%20And%20Metformin%20Are%20Eliminated%20From%20The%20Body%20When%20They%20Are%20Administered%20At%20The%20Same%20Time</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>February 16, 2010</last_update_submitted>
  <last_update_submitted_qc>February 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>metformin, PD 0332334, organic cation transporter, OCT2, pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

